Hot startup Theranos dials back lab tests at FDA's behest

Under pressure from regulators, laboratory firm Theranos Inc. has stoppe d collecting tiny vials of blood drawn from finger pricks for all but one of its tests, according to a person familiar with the matter, backing away from a method the company has touted as it rose to become one of Silicon Valley's hottest startups. The move is a setback to the Palo Alto, Calif., company's ambition to revolutionize the blood-testing industry. As a result of the halt, Theranos is operating more like a traditional lab that draws blood with needles from patients' arms. Theranos is valued at $9 billion, or about as much as each of the industry's two largest companies in the U.S. [Subscription Required]